Yonsei Med J.  2007 Apr;48(2):274-280. 10.3349/ymj.2007.48.2.274.

The Effect of Hepatitis C Virus Infection on Insulin Resistance in Chronic Haemodialysis Patients

• Ozdemir A
• Yalinbas B
• Selamet U
• Eres M
• Turkmen F
• Kumbasar F
• Murat B
• Keskin AT
• Barut Y

• KMID: 1779531
• DOI: http://doi.org/10.3349/ymj.2007.48.2.274

Abstract

PURPOSE
To investigate the contribution of HCV infection to insulin resistance in chronic haemodialysis patients. MATERIALS AND METHODS: The study was performed with 55 patients who were on regular haemodialysis therapy three times per week. Of the 55 patients, 34 (20 females and 14 males with an average age of 40.9 years) were anti-HCV (+) and were defined as the HCV (+) group. The remaining 21 patients (8 females and 11 males with an average age of 50 years) were negative for HCV and other viral markers and were defined as the HCV (-) group. BMI of all patients were below 27. Insulin resistance (IR) was calculated according to the HOMA formula and patients were called HOMA-IR (+) if their HOMA scores were higher than 2.5. All of the HOMA-IR (+) patients in both groups were called the HOMA-IR (+) subgroup. None of the patients had a history of drug use or any diseases that were related to insulin resistance except uremia. In both groups and the healthy control group, insulin and glucose levels were studied at three different venous serum samples taken at 5- minute intervals after 12 hours of fasting. Other individual variables were studied at venous serum samples taken after 12 hours of fasting. RESULTS: HOMA scores were (3)2.5 in 22 of 34 HCV (+) patients (64.7%) and 7 of 21HCV (-) patients (33.33%) (p=0.024). Insulin levels of HCV (+) group (13.32 +/- 9.44mIU/mL) were significantly higher than HCV (-) (9.07 +/- 7.39mIU/mL) and the control groups (6.40 +/- 4.94mIU/ mL) (p=0.039 and p=0.021 respectively). HCV (+) patients were younger (40.94 +/- 17.06 and 52.62 +/- 20.64 years, respectively) and had longer dialysis duration (7.18 +/- 3.61 and 2.91 +/- 2.69 years, respectively). Significant positive correlations of HOMA score with insulin (r=0.934, p=0.000) and fasting glucose levels (r=0.379, p=0.043) were found in the HOMA- IR (+) subgroup. Also, a significant positive correlation was found between ALT and insulin levels in the HOMA IR (+) subgroup. C-peptide levels of both HCV (+) and (-) groups were significantly higher than the control group (p < 0.001). There were not any significant correlations between HOMA score and some of the other individual variables including levels of triglyceride, ferritin, ALT, iPTH and Mg in any of the groups. CONCLUSION: In chronic haemodialysis patients; HCV infection is related to a high prevalence of insulin resistance, higher insulin and glucose levels.

Keyword

Insulin resistance; HCV; haemodialysis

MeSH Terms

*Renal Dialysis
Middle Aged
Male
Kidney Failure, Chronic/*complications
*Insulin Resistance
Insulin/blood
Hyperinsulinism/epidemiology
Humans
Hepatitis C/*epidemiology
Female
C-Peptide/blood
Adult

Reference

1. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Peitte JC, et al. Extrahepatic manifestations of chronic hepatitis C MULTIVIRC Group Multidepartment Virus C. Arthritis Rheum. 1999. 42:2204–2212.

2. Ignatova TM, Aprosina ZG, Serov VV, Mukhin NA, Krel' PE, Semenkova EN, et al. Extrahepatic manifestations of chronic hepatitis C. Ter Arkh. 1998. 70:9–16.

3. Donada C, Crucitti A, Donadon V, Tommasi L, Zanette G, Crovatto M, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type or mixed cryoglobulinaemia. J Viral Hepat. 1998. 5:179–185.

4. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000. 133:592–599.

5. Caronia S, Taylor K, Pagliara L, Carr C, Palazzo U, Petrik J, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999. 30:1059–1063.

6. Alexander GJ. An association between hepatitis C virus infection and type 2 diabetes mellitus: What is the connection? Ann Intern Med. 2000. 133:650–652.

7. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999. 29:328–333.

8. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in non cirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000. 75:355–359.

9. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994. 21:1135–1139.

10. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology. 2000. 32:87–90.

11. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care. 1996. 19:998–1000.

12. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors of diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001. 35:279–283.

13. el-Zayadi AR, Selim OE, Hamdy H, Dabbous H, Ahdy A, Moniem SA. Association of chronic hepatitis C infection and diabetes mellitus. Trop Gastroenterol. 1998. 19:141–144.

14. Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol. 1996. 20:544–548.

15. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981. 67:563–568.

16. Bagdade JD. Disorders of glucose metabolism in uremia. Adv Nephrol Necker Hosp. 1979. 8:87–100.

17. Rasic-Milutinovic Z, Perunicic-Pekovic G. Clinical importance and pathogenetic mechanisms of insulin resistance in chronic renal insufficiency (part I): Insulin resistance in patients with chronic renal insufficiency. Med Pregl. 2000. 53:45–50.

18. Shoji T, Emoto M, Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron. 2001. 89:348–349.

19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. 28:412–419.

20. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998. 21:2191–2192.

21. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal failure. J Am Soc Nephrol. 2002. 13:1894–1900.

22. Yıldız A, Tutuncu Y, Yazıcı H, Akkaya V, Kayacan SM, Sever MS, et al. Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation. 2002. 74:1109–1113.

23. Kobayashi S, Maejima S, İkeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2000. 15:65–70.

24. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index a non-diabetic population. Med Clin (Barc). 2001. 117:530–533.

25. Regeur L, Faber OK, Binder C. Plasma C-peptide in uremic patients. Scand J Clin Lab Invest. 1978. 38:771–775.

26. Fabrizi F, Lunghi G, Finazzi S, Colucci P, Pagano A, Ponticelli C, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: Impact on the detection of viral hepatitis. Am J Kidney Dis. 2001. 38:1009–1015.

27. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002. 36:3–10.

28. Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Serum alanine aminotransferase in hepatitis c screening of patients on haemodialysis. Am J Kidney Dis. 2001. 37:308–315.

29. Yasudu K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, et al. Hypoaminotransferasemia in patients undergoing long-term haemodialysis: clinical and biochemical appraisal. Gastroenterology. 1995. 109:1295–1300.

30. Taniguchi A, Nakai Y, Sakai M, Yoshii S, Hamanaka D, Hatae Y, et al. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. Metabolism. 2002. 51:544–548.

31. Caro JF. Clinical review 26: insulin resistance in obese and nonobese man. J Clin Endocrinol Metab. 1991. 73:691–695.

32. Hernandez C, Genesca J, Ignasi Esteban J, Garcia L, Simo R. Relationship between iron stores and diabetes mellitus in patients infected by hepatitis C virus: a case-control study. Med Clin(Barc). 2000. 115:21–22.

33. Hague S, Chandra B, Gerber MA, Lok AS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol. 1996. 27:1277–1281.

34. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998. 53:1353–1357.

35. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int. 1995. 47:200–206.

36. Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J. 2001. 94:1195–1201.